Meridian Wealth Management’s DiaMedica Therapeutics DMAC Stock Holding History

Meridian Wealth Management’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$329K	Sell	48,641 -2,000	-4%	-$15.8K	0.01%	625
2025 Q4	$403K	Sell	50,641 -1,025	-2%	-$7.67K	0.01%	549
2025 Q3	$355K	Buy	51,666 +24,350	+89%	+$132K	0.01%	552
2025 Q2	$107K	Sell	27,316 -1,500	-5%	-$5.85K	﹤0.01%	655
2025 Q1	$109K	Buy	28,816 +1,600	+6%	+$9.15K	0.01%	605
2024 Q4	$148K	Buy	+27,216	New	+$128K	0.01%	610

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Meridian Wealth Management's DMAC Position: Q1 2026 in Review

Meridian Wealth Management reduced its DiaMedica Therapeutics (DMAC) stake by 3.9% in Q1 2026, selling an estimated $15.8K and leaving 48,641 shares worth $329K. The position accounts for 0.01% of the portfolio, ranked #625.

Meridian Wealth Management first reported a position in DMAC in Q4 2024 and has held it in 6 quarters since. The position peaked at $403K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

Meridian Wealth Management held 48,641 shares of DiaMedica Therapeutics worth $329K as of Q1 2026.
Meridian Wealth Management sold 2,000 DiaMedica Therapeutics shares in Q1 2026, an estimated $15.8K.
DiaMedica Therapeutics made up 0.01% of Meridian Wealth Management's portfolio in Q1 2026, its #625 holding.
Meridian Wealth Management first reported a position in DiaMedica Therapeutics in Q4 2024 and has held it in 6 quarters since.
Meridian Wealth Management's DiaMedica Therapeutics position peaked at $403K in Q4 2025.
98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Meridian Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.